Therapeutic Asset Ratings

139 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Allogeneic Natural Killer Cells Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Paolo Caimi, MD	P1	C (35)
Anti-Cd19 Car Nk Cells Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Xuzhou Medical University	Early P1	C (34)
Allo-Quadcar01-T Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	AvenCell Therapeutics, Inc.		D (28)
Allo-Revcar01-T Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	AvenCell Therapeutics, Inc.		D (28)
Ari-0001 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	GUSTAVO SALGUERO	N/A	D (28)
GLUCOSE, ANHYDROUS Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	University of Wisconsin, Madison		D (28)
Glutamine Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	University of Wisconsin, Madison		D (28)
Prevnar Chronic Lymphocytic Leukemia	Massachusetts General Hospital		D (28)
Quadrivalent Inactivated Influenza Vaccine Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Emory University		D (28)
R-Tm123 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	AvenCell Therapeutics, Inc.		D (28)
tm123 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	AvenCell Therapeutics, Inc.		D (28)
Unicar02-T-Ppsma Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	AvenCell Therapeutics, Inc.		D (28)
gi-4000 Chronic Lymphocytic Leukemia	Massachusetts General Hospital		D (27)
Unicar02-T Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	AvenCell Therapeutics, Inc.		D (26)

Showing 126 to 139 of 139 assets

PreviousPage 6 of 6Next